$ESPERION THERAPEUTICS INC NE(ESPR)$ 为什么有利好消息，他还跌了这么多？
Esperion looks to disrupt the PCSK9 race with new cardio data
July 28, 2015 | By Damian Garde
Esperion ($ESPR), developing a pill it hopes can eventually cut in on some would-be blockbusters, posted new study results showing that its drug both reduced bad cholesterol and improved inflammation.

In an exploratory Phase II trial, Esperion's ETC-1002 significantly beat out placebo in treating patients with both high cholesterol and high blood pressure. In the 143-patient trial, ETC-1002 met its primary goal by notching a 21% reduction in LDL, or bad, cholesterol from baseline, compared to a 3% increase with placebo.

And the drug came through on its secondary endpoint of reducing high-sensitivity C-reactive protein, or hsCRP, which is a marker of inflammation in coronary disease. ETC-1002 lowered hsCRP 25% from baseline and a whopping 44% compared with placebo. Esperion said the drug had a "neutral" effect on blood pressure, another secondary goal, but the company did not disclose detailed data.